These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

367 related items for PubMed ID: 11779081

  • 1. Endothelial survival factors as targets for antineoplastic therapy.
    Reinmuth N, Stoeltzing O, Liu W, Ahmad SA, Jung YD, Fan F, Parikh A, Ellis LM.
    Cancer J; 2001; 7 Suppl 3():S109-19. PubMed ID: 11779081
    [Abstract] [Full Text] [Related]

  • 2. Antiangiogenic therapy targeting factors that enhance endothelial cell survival.
    Liu W, Reinmuth N, Stoeltzing O, Parikh AA, Fan F, Ahmad SA, Jung YD, Ellis LM.
    Semin Oncol; 2002 Jun; 29(3 Suppl 11):96-103. PubMed ID: 12138403
    [Abstract] [Full Text] [Related]

  • 3. Advances in the use of angiogenesis inhibitors in cancer.
    Pinedo HM.
    Cancer J; 2001 Jun; 7 Suppl 3():S107-8. PubMed ID: 11779080
    [No Abstract] [Full Text] [Related]

  • 4. The clinical implications of angiogenesis in the treatment of cancer.
    Aoun E, Taher A.
    J Med Liban; 2002 Jun; 50(1-2):32-8. PubMed ID: 12841311
    [Abstract] [Full Text] [Related]

  • 5. SU6668, a multitargeted angiogenesis inhibitor.
    Hoekman K.
    Cancer J; 2001 Jun; 7 Suppl 3():S134-8. PubMed ID: 11779084
    [Abstract] [Full Text] [Related]

  • 6. Angiogenesis inhibition in solid tumors.
    Rosen LS.
    Cancer J; 2001 Jun; 7 Suppl 3():S120-8. PubMed ID: 11779082
    [Abstract] [Full Text] [Related]

  • 7. Role of angiogenesis inhibitors in acute myeloid leukemia.
    Fiedler W, Staib P, Kuse R, Dührsen U, Flasshove M, Cavalli F, Hossfeld DK, Berdel WE.
    Cancer J; 2001 Jun; 7 Suppl 3():S129-33. PubMed ID: 11779083
    [Abstract] [Full Text] [Related]

  • 8. Endothelial cell survival and apoptosis in the tumor vasculature.
    Liu W, Ahmad SA, Reinmuth N, Shaheen RM, Jung YD, Fan F, Ellis LM.
    Apoptosis; 2000 Oct; 5(4):323-8. PubMed ID: 11227213
    [Abstract] [Full Text] [Related]

  • 9. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis.
    Cheng N, Brantley DM, Liu H, Lin Q, Enriquez M, Gale N, Yancopoulos G, Cerretti DP, Daniel TO, Chen J.
    Mol Cancer Res; 2002 Nov; 1(1):2-11. PubMed ID: 12496364
    [Abstract] [Full Text] [Related]

  • 10. Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2.
    Vajkoczy P, Farhadi M, Gaumann A, Heidenreich R, Erber R, Wunder A, Tonn JC, Menger MD, Breier G.
    J Clin Invest; 2002 Mar; 109(6):777-85. PubMed ID: 11901186
    [Abstract] [Full Text] [Related]

  • 11. NERF2, a member of the Ets family of transcription factors, is increased in response to hypoxia and angiopoietin-1: a potential mechanism for Tie2 regulation during hypoxia.
    Christensen RA, Fujikawa K, Madore R, Oettgen P, Varticovski L.
    J Cell Biochem; 2002 Mar; 85(3):505-15. PubMed ID: 11967990
    [Abstract] [Full Text] [Related]

  • 12. A targeted approach for antiangiogenic therapy of metastatic human colon cancer.
    Ellis LM.
    Am Surg; 2003 Jan; 69(1):3-10. PubMed ID: 12575772
    [Abstract] [Full Text] [Related]

  • 13. Anticancer drug targets: approaching angiogenesis.
    Keshet E, Ben-Sasson SA.
    J Clin Invest; 1999 Dec; 104(11):1497-501. PubMed ID: 10587512
    [No Abstract] [Full Text] [Related]

  • 14. Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms.
    Shaheen RM, Tseng WW, Davis DW, Liu W, Reinmuth N, Vellagas R, Wieczorek AA, Ogura Y, McConkey DJ, Drazan KE, Bucana CD, McMahon G, Ellis LM.
    Cancer Res; 2001 Feb 15; 61(4):1464-8. PubMed ID: 11245452
    [Abstract] [Full Text] [Related]

  • 15. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF.
    Holash J, Wiegand SJ, Yancopoulos GD.
    Oncogene; 1999 Sep 20; 18(38):5356-62. PubMed ID: 10498889
    [Abstract] [Full Text] [Related]

  • 16. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro.
    Abdollahi A, Lipson KE, Han X, Krempien R, Trinh T, Weber KJ, Hahnfeldt P, Hlatky L, Debus J, Howlett AR, Huber PE.
    Cancer Res; 2003 Jul 01; 63(13):3755-63. PubMed ID: 12839971
    [Abstract] [Full Text] [Related]

  • 17. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis.
    Saaristo A, Karpanen T, Alitalo K.
    Oncogene; 2000 Dec 11; 19(53):6122-9. PubMed ID: 11156525
    [Abstract] [Full Text] [Related]

  • 18. Immunohistochemical study of VEGF, angiopoietin 2 and their receptors in the neovascularization following microinjection of C6 glioma cells into rat brain.
    Péoch M, Farion R, Hiou A, Le Bas JF, Pasquier B, Rémy C.
    Anticancer Res; 2002 Dec 11; 22(4):2147-51. PubMed ID: 12174896
    [Abstract] [Full Text] [Related]

  • 19. Angiogenesis in health and disease: insights into basic mechanisms and therapeutic opportunities.
    Polverini PJ.
    J Dent Educ; 2002 Aug 11; 66(8):962-75. PubMed ID: 12214844
    [Abstract] [Full Text] [Related]

  • 20. Tumour vasculature as a target for anticancer therapy.
    Eatock MM, Schätzlein A, Kaye SB.
    Cancer Treat Rev; 2000 Jun 11; 26(3):191-204. PubMed ID: 10814561
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.